Call For More Information (410) Skype715-2111
Blog: Recent Posts
  1. ACOG Opinion on Noninvasive Prenatal Genetic Testing

    Noninvasive Prenatal Testing for Fetal Aneuploidy ABSTRACT: Noninvasive prenatal testing that uses cell free fetal DNA from the plasma of pregnant women offers tremendous potential as a screening tool for fetal aneuploidy. Cell free fetal DNA testing should be an informed patient choice after pretest counseling and should not be...
  2. Choosing to Participate in Prenatal Screening for Down Syndrome

    New prenatal screening test for Down syndrome raises questions LEISA SCOTT IT RAINED the day they got the news. Big, pelting drops, as if some screenwriter well-versed in melodrama was dictating the scene. Annie Love couldn’t take the call. She’d been going “slowly nuts” waiting for diagnosis day to arrive...

Single Gene Disorder Testing

Ravgen’s ability to increase the percentage of fetal DNA present in blood from the pregnant mother allows noninvasive prenatal genetic testing for single gene disorders, such as cystic fibrosis and sickle cell anemia. When a pregnant mother and her partner are both carriers for a recessive single gene disorder, they have a 1 in 4 chance of having a baby affected with that genetic condition, or 2 in 4 chance of having a baby that is a carrier.

Ravgen’s noninvasive prenatal single-gene disorder testing is a safer and earlier alternative than invasive tests like chorionic villi sampling (CVS) or amniocentesis. Single gene disorders that can be tested by noninvasive prenatal testing include cystic fibrosis, sickle cell anemia, spinal muscular atrophy, Duchenne muscular dystrophy, and any other single-gene disorder for which the mutation is known. Ravgen welcomes inquiries regarding prenatal tests which are not seen here as our laboratory is continuously moving forward in the field.